OrbiMed’s Bristol-Myers Squibb BMY Stock Holding History

OrbiMed’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-200,000	Closed	-$10.9M	–	141
2017 Q1	$10.9M	Buy	+200,000	New	+$11M	0.12%	93

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed's BMY Position: Q2 2026 in Review

OrbiMed held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 925,000 shares worth $53.3M. The position accounts for 0.99% of the portfolio, ranked #33.

OrbiMed first reported a position in BMY in Q2 2013 and has held it in 43 quarters since. The position peaked at $577M in Q4 2015. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

OrbiMed held 925,000 shares of Bristol-Myers Squibb worth $53.3M as of Q2 2026.
OrbiMed left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.99% of OrbiMed's portfolio in Q2 2026, its #33 holding.
OrbiMed first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 43 quarters since.
OrbiMed's Bristol-Myers Squibb position peaked at $577M in Q4 2015.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.